NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
FREMONT, Calif., March 09, 2016 -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage specialty pharmaceutical company, today announced that Konstantinos Alataris, Ph.D., President and Chief Executive Officer of Zosano, will provide a company overview at the 28th Annual ROTH Conference on March 14, 2016. The presentation will take place at 8:00 a.m. PT at the Ritz Carlton Hotel in Laguna Niguel, California.
To access the presentation, please visit the Zosano website at www.zosanopharma.com. Under the "Investors" tab, select the link to "Events & Presentations."
About Zosano Pharma
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company that has developed a proprietary transdermal microneedle patch system to deliver drug formulations through the skin for the treatment of a variety of indications. Zosano Pharma's microneedle patch system offers rapid onset, consistent drug delivery, improved ease of use and room-temperature stability, benefits that the company believes often are unavailable using oral formulations or injections. Zosano Pharma's microneedle patch system has the potential to deliver numerous medications for a wide variety of indications in commercially attractive markets. It has been tested in more than 400 patients with over 30,000 patches successfully applied to humans in Phase 1 and Phase 2 clinical studies. Learn more at www.zosanopharma.com.
Corporate Contact: Konstantinos Alataris President and Chief Executive Officer 510-745-1200 Investor Contact: Patti Bank Westwicke Partners 415-513-1284 [email protected] Media Contact: Jamie Lacey-Moreira 410-299-3310 [email protected]
